Combination treatment with tenapanor and sevelamer synergistically reduces urinary phosphorus excretion in rats.
Abstract The majority of patients with chronic kidney disease (CKD) receiving dialysis do not reach target serum phosphorus concentrations, despite treatment with phosphate binders. Tenapanor is a non-binder, sodium/hydrogen exchanger isoform 3 (NHE3) inhibitor that reduces paracellular intestinal phosphate absorption. This pre-clinical study evaluated the effect of tenapanor and varying doses of sevelamer carbonate on urinary phosphorus excretion, a direct reflection of intestinal phosphate absorption. We measured 24-hour urinary phosphorus excretion in male rats assigned to groups dosed orally with vehicle or te...
Source: American Journal of Physiology. Renal Physiology - December 7, 2020 Category: Physiology Authors: King AJ, Kohler J, Fung C, Jiang Z, Quach A, Kumaraswamy P, Chertow GM, Rosenbaum DP Tags: Am J Physiol Renal Physiol Source Type: research
Characteristics of Patients Who Achieve Serum Phosphorus Control on Sucroferric Oxyhydroxide or Sevelamer Carbonate: A post hoc Analysis of a Phase 3 Study
Conclusion: This analysis indicates that sP control may be more challenging in younger patients with high sP levels. Closer monitoring and management of serum phosphorus levels may be required in this population.Nephron (Source: Nephron)
Source: Nephron - June 25, 2020 Category: Urology & Nephrology Source Type: research
Effect of calcitriol combined with sevelamer carbonate on serum parathyroid hormone in patients with chronic renal failure.
This study aimed to observe and analyze the effect of calcitriol combined with sevelamer carbonate on serum parathyroid hormone in patients with chronic renal failure. This study included 180 patients who had been treated for chronic renal failure in our hospital were enrolled as research objects. The patients were randomly divided into two groups: a research group and a control group, each containing 90 cases. The research group was treated with calcitriol combined with sevelamer carbonate, and the control group was treated with calcitriol alone. The therapeutic effects of the two groups were observed and analyzed by...
Source: Cellular and Molecular Biology - May 18, 2020 Category: Molecular Biology Tags: Cell Mol Biol (Noisy-le-grand) Source Type: research
Effects of Sevelamer Carbonate in Patients With CKD and Proteinuria: The ANSWER Randomized Trial
Conclusions3-month sevelamer treatment did not reduce proteinuria in patients with CKD on maximal RAS blockade. Amelioration of inflammation and dyslipidemia with sevelamer treatment raises the possibility that it may confer benefit in patients with CKD beyond reduction of proteinuria.FundingSanofi (Milan, Italy).Trial RegistrationRegistered at ClinicalTrials.gov with study number NCT01968759. (Source: American Journal of Kidney Diseases)
Source: American Journal of Kidney Diseases - June 20, 2019 Category: Urology & Nephrology Source Type: research
Phosphate binders, appetite and nutritional status in maintenance hemodialysis patients.
CONCLUSIONS: Regular use of these phosphate binders was not associated with anorexia, decreased dietary intake and nutritional status in the study population. Therefore, there is no preference in the choice of phosphate binders in MHD patients with hyperphosphatemia, even those who are at nutritional risk. PMID: 30485918 [PubMed - in process] (Source: Asia Pacific Journal of Clinical Nutrition)
Source: Asia Pacific Journal of Clinical Nutrition - December 3, 2018 Category: Nutrition Authors: Beberashvili I, Baskin O, Azar A, Katkov A, Feldman L, Gorelik O, Stav K, Efrati S Tags: Asia Pac J Clin Nutr Source Type: research
In-vitro Equilibrium Phosphate Binding Study of Sevelamer Carbonate by UV-Vis Spectrophotometry
Drug Res (Stuttg) DOI: 10.1055/a-0635-8246Sevelamer carbonate is a cross-linked polymeric amine; it is the active ingredient in Renvela® tablets. US FDA provides recommendation for demonstrating bioequivalence for the development of a generic product of sevelamer carbonte using in-vitro equilibrium binding study. A simple UV-vis spectrophotometry method was developed and validated for quantification of free phosphate to determine the binding parameter constant of sevelamer. The method validation demonstrated the specificity, limit of quantification, accuracy and precision of measurements. The validated method has been ...
Source: Drug Research - June 12, 2018 Category: Drugs & Pharmacology Authors: Prasaja, Budi Syabani, M. Maulana Sari, Endah Chilmi, Uci Cahyaningsih, Prawitasari Kosasih, Theresia Weliana Tags: Original Article Source Type: research
Influence of pH and phosphate concentration on the phosphate binding capacity of five contemporary binders. An in vitro study
Abstract IntroductionHyperphosphatemia is associated with increased mortality and morbidity in end stage renal disease. Despite phosphate binder therapy, a large proportion of patients does not reach the treatment target. In five contemporary binders we explored the influence of pH and phosphate concentration on phosphate binding. . This interaction could be of relevance in clinical practice. MethodsPhosphate binding was quantified in vitro in 25 ml of purified water containing phosphate concentrations of 10, 15 and 20 mM and baseline pH values of 3.0 or 6.0, with a binder over 6 hours. Lanthanum carbonate, calcium acetate...
Source: Nephrology - February 26, 2018 Category: Urology & Nephrology Authors: Stefan P Schumacher, LJ Schurgers, G Vervloet Marc, Aegida Neradova Tags: Original Article Source Type: research
Sevelamer-Induced Gastrointestinal Injury Presenting as Gastroenteritis
End-stage renal disease (ESRD) is a common disease encountered in clinical practice and is associated with increasing metabolic derangements through disease progression. Phosphate retention is one of the most common derangements and is associated with increased mortality. Hyperphosphatemia becomes increasingly prevalent as glomerular filtration rate decreases. Non-calcium phosphate-binding resins and dietary phosphate restriction are the mainstays for managing hyperphosphatemia in patients with ESRD. Sevelamer carbonate is the most frequently used non-calcium phosphate binder in the US due to ease of administration and an ...
Source: Case Reports in Gastroenterology - February 1, 2018 Category: Gastroenterology Source Type: research
Efficacy and safety of sevelamer carbonate in hyperphosphatemic pediatric patients with chronic kidney disease
AbstractBackgroundTreatment for hyperphosphatemia in chronic kidney disease (CKD) involves dietary control of phosphorus intake, dialysis, and treatment with oral phosphate binders, none of which were approved by the Federal Food and Drug Administration in pediatric patients at the time of this study.MethodsThis was a phase 2, multicenter study (NCT01574326) with a 2-week, randomized, placebo-controlled, fixed-dose period (FDP) followed by a 6-month, single-arm, open-label, dose-titration period (DTP), with the aim to evaluate the safety and efficacy of sevelamer carbonate (SC) in hyperphosphatemic pediatric patients with ...
Source: Pediatric Nephrology - January 15, 2018 Category: Urology & Nephrology Source Type: research
Randomized Clinical Trial of Sevelamer Carbonate on Serum Klotho and Fibroblast Growth Factor 23 in CKD.
CONCLUSIONS: In our double-blind, placebo-controlled, randomized study performed in normophosphatemic patients with CKD, a 12-week course of sevelamer carbonate significantly reduced phosphaturia without changing serum phosphorus but did not significantly modify serum C-terminal fibroblast growth factor 23 and intact fibroblast growth factor 23 or α-klotho levels. PMID: 29074818 [PubMed - as supplied by publisher] (Source: Clinical Journal of the American Society of Nephrology : CJASN)
Source: Clinical Journal of the American Society of Nephrology : CJASN - October 26, 2017 Category: Urology & Nephrology Authors: Liabeuf S, Ryckelynck JP, El Esper N, Ureña P, Combe C, Dussol B, Fouque D, Vanhille P, Frimat L, Thervet E, Mentaverri R, Prié D, Choukroun G, FRENCH Study collaborators Tags: Clin J Am Soc Nephrol Source Type: research
Pharmacoeconomic Assessment of Sucroferric Oxyhydroxide Vs Sevelamer Carbonate In Patients With Chronic Kidney Disease In Belgium and The Netherlands
Sucroferric oxyhydroxide (SFOH) is a non-calcium, iron-based phosphate binder indicated for the control of serum phosphorus (sPhos) levels in chronic kidney disease patients on hemodialysis or peritoneal dialysis. A US retrospective analysis demonstrated that, after 3 and 6 months, switching from sevelamer (SEV) to SFOH increased the proportion of patients with in-range sPhos (3.5-5.5 mg/dl) by 74-98%, while reducing pill burden (PB) by 61-62%. Post-hoc analyses of SFOH showed no apparent interaction with oral Vitamin D (VDRAs) contrary to SEV ’s potential interactions. (Source: Value in Health)
Source: Value in Health - October 1, 2017 Category: International Medicine & Public Health Authors: N Kotsopoulos, M Connolly, P Vrouchou, S Walpen, H Smeenge, J van Stiphout Source Type: research
Initiation of Sevelamer and Mortality among Hemodialysis Patients Treated with Calcium-Based Phosphate Binders.
CONCLUSIONS: The use of sevelamer as an add-on or alternative therapy to calcium-based phosphate binders is associated with improved survival in patients on maintenance hemodialysis. PMID: 28724618 [PubMed - as supplied by publisher] (Source: Clinical Journal of the American Society of Nephrology : CJASN)
Source: Clinical Journal of the American Society of Nephrology : CJASN - July 19, 2017 Category: Urology & Nephrology Authors: Komaba H, Wang M, Taniguchi M, Yamamoto S, Nomura T, Schaubel DE, Smith AR, Zee J, Karaboyas A, Bieber B, Fukagawa M, Tentori F Tags: Clin J Am Soc Nephrol Source Type: research
Preclinical and Healthy Volunteer Studies of Potential Drug –Drug Interactions between Tenapanor and Phosphate Binders
This article is protected by copyright. All rights reserved (Source: Clinical Pharmacology in Drug Development)
Source: Clinical Pharmacology in Drug Development - September 21, 2016 Category: Drugs & Pharmacology Authors: Susanne Johansson, Maria Leonsson ‐Zachrisson, Mikael Knutsson, Andrew G. Spencer, Eric D. Labonté, Desiree Deshpande, Jill Kohler, Kenji Kozuka, Dominique Charmot, David P. Rosenbaum Tags: Original Manuscript Source Type: research
Pharmacodynamic Effects of Sucroferric Oxyhydroxide and Sevelamer Carbonate on Vitamin D Receptor Agonist Bioactivity in Dialysis Patients.
CONCLUSIONS: In contrast with SEV, SFOH did not appear to impact the iPTH-lowering effect of oral VDRAs. PMID: 27434393 [PubMed - as supplied by publisher] (Source: American Journal of Nephrology)
Source: American Journal of Nephrology - July 19, 2016 Category: Urology & Nephrology Authors: Sprague SM, Covic AC, Floege J, Ketteler M, Botha J, Chong EM, Rastogi A Tags: Am J Nephrol Source Type: research
Pharmacodynamic Effects of Sucroferric Oxyhydroxide and Sevelamer Carbonate on Vitamin D Receptor Agonist Bioactivity in Dialysis Patients
Conclusions: In contrast with SEV, SFOH did not appear to impact the iPTH-lowering effect of oral VDRAs.Am J Nephrol 2016;44:104-112 (Source: American Journal of Nephrology)
Source: American Journal of Nephrology - July 19, 2016 Category: Neurology Source Type: research
Adherence rates to ferric citrate as compared to active control in patients with end stage kidney disease on dialysis
Discussion Adherence rates to the phosphate binder, ferric citrate, were similar to adherence rates to active control. Similar adherence rates to ferric citrate are notable since tolerance to active control was an entry criteria and the study was open label. Gender, race/ethnicity, nor age influenced adherence. (Source: Hemodialysis International)
Source: Hemodialysis International - June 30, 2016 Category: Hematology Authors: Diana Jalal, Molly McFadden, Jamie P. Dwyer, Kausik Umanath, Erwin Aguilar, Yoram Yagil, Barbara Greco, Mohammed Sika, Julia B. Lewis, Tom Greene, Simin Goral Tags: Original Article Source Type: research
Sevelamer carbonate reduces the risk of hypomagnesemia in hemodialysis-requiring end-stage renal disease patients
Background Sevelamer has been associated with less progression of vascular calcifications. This effect could be due to a reduction in serum phosphate levels but also to other additive effects. Magnesium has been also shown to prevent vascular calcification but the effect of sevelamer on serum magnesium levels has not been thoroughly evaluated. Our aim was to analyze whether the use of sevelamer reduces the risk of hypomagnesemia in hemodialysis (HD)-requiring end-stage renal disease patients. Methods All prevalent patients from the dialysis unit of the Hospital Italiano de Buenos Aires as of 1 June 2015 were evaluated. Th...
Source: CKJ: Clinical Kidney Journal - May 30, 2016 Category: Urology & Nephrology Authors: Rosa-Diez, G., Negri, A. L., Crucelegui, M. S., Philippi, R., Perez-Teysseyre, H., Sarabia-Reyes, C., Loor-Navarrete, H., Heguilen, R. Tags: DIALYSIS Source Type: research
Sp332 * sevelamer carbonate reduces inflammation in human endothelial cells exposed to advanced glycation end products (ages)
(Source: Nephrology Dialysis Transplantation)
Source: Nephrology Dialysis Transplantation - May 13, 2016 Category: Urology & Nephrology Authors: Gregorio, P., Favretto, G., Sassaki, G., da Cunha, R., Becker-Finco, A., Pecoits-Filho, R., Souza, W., Barreto, F., Stinghen, A. Tags: CHRONIC KIDNEY DISEASE. NUTRITION, INFLAMMATION AND OXIDATIVE STRESS Source Type: research
Mp591 * cost-minimisation analysis of sucroferric oxyhydroxide and sevelamer carbonate in patients on dialysis with secondary hyperparathyroidism in the united kingdom
(Source: Nephrology Dialysis Transplantation)
Source: Nephrology Dialysis Transplantation - May 13, 2016 Category: Urology & Nephrology Authors: van Stiphout, J., Braunhofer, P. G., Rakov, V., Schwenkglenks, M., Szucs, T. D., Blank, P. R. Tags: DIALYSIS. EPIDEMIOLOGY, OUTCOME RESEARCH, HEALTH SERVICES RESEARCH - 2 Source Type: research
Epicardial adipose tissue volume increase in hemodialysis patients treated with sevelamer or calcium-based phosphate binders: a substudy of the Renagel in new dialysis trial.
Abstract BACKGROUND: In the general population and in hemodialysis patients epicardial adipose tissue (EAT) has been associated with increased mortality and cardiovascular events. Weight loss and lipid lowering therapies reduced EAT in the general population. It is unknown whether sevelamer, a phosphate (Pi) binder that lowers cholesterol and reduces inflammation in dialysis patients also affects EAT progression. METHODS: Post-hoc analysis of a randomized trial of sevelamer (SVL) versus calcium-based Pi binders (CPiB) in incident hemodialysis patients. EAT was measured on cardiac computed tomography scans per...
Source: Journal of Nephrology - April 20, 2016 Category: Urology & Nephrology Authors: Ko SM, Zhang C, Chen Z, D'Marco L, Bellasi A, Stillman AE, Block G, Raggi P Tags: J Nephrol Source Type: research
Phosphate binders for the treatment of chronic kidney disease: role of iron oxyhydroxide.
In conclusion, the overall benefit-risk balance of sucroferric oxyhydroxide is deemed to be positive, and this new drug may therefore represent a good alternative to traditional phosphate binders for the treatment of hyperphosphatemia in dialysis patients. PMID: 26893577 [PubMed] (Source: International Journal of Nephrology and Renovascular Disease)
Source: International Journal of Nephrology and Renovascular Disease - February 20, 2016 Category: Urology & Nephrology Tags: Int J Nephrol Renovasc Dis Source Type: research
Moderator's view: Phosphate binders in chronic kidney disease patients: a clear 'No at the moment, but stay tuned
Particularly because the risk of harm cannot be safely excluded, the use of phosphate binders in chronic kidney disease (CKD) patients demands caution. Yet, the clinical inertia concerning phosphate burden is unjustified. Inorganic, phosphate esters added to preserve food represent an important component of dietary phosphate load. These compounds are easily absorbable and have a measurable effect on serum phosphate, and therefore their use should be avoided in CKD patients. The ongoing CKD Optimal management with Binders and NicotinamidE (COMBINE) study, applying chelation by phosphate binders and intestinal Na–P cha...
Source: Nephrology Dialysis Transplantation - January 25, 2016 Category: Urology & Nephrology Authors: Zoccali, C., Mallamaci, F. Tags: POLAR VIEWS IN NEPHROLOGY Source Type: research
A randomized, double-blind, placebo-controlled, dose-ranging study using Genz-644470 and sevelamer carbonate in hyperphosphatemic chronic kidney disease patients on hemodialysis.
CONCLUSION: Both Genz-644470 and sevelamer carbonate effectively lowered serum phosphate levels in a dose-dependent fashion in patients with chronic kidney disease on hemodialysis. However, Genz-644470 did not provide any advantage over sevelamer carbonate in phosphate lowering in vivo, as had been demonstrated in vitro. PMID: 24748812 [PubMed] (Source: International Journal of Nephrology and Renovascular Disease)
Source: International Journal of Nephrology and Renovascular Disease - November 28, 2015 Category: Urology & Nephrology Tags: Int J Nephrol Renovasc Dis Source Type: research
Cost-Minimization Analysis of Direct Cost of Sevelamer Carbonate and Lanthanum Carbonate in the Treatment of Patients with Chronic Kidney Disease Not on Dialysis in Bulgaria
Conclusions The equal efficacy, similar adverse effect profile, and lower cost of SC when used for the treatment of hyperphosphatemia in patients with CKD not on dialysis should make it a preferred alternative. (Source: Value in Health Regional Issues)
Source: Value in Health Regional Issues - November 13, 2015 Category: Global & Universal Source Type: research
Ferric Citrate Reduces Intravenous Iron and Erythropoiesis-Stimulating Agent Use in ESRD
Ferric citrate (FC) is a phosphate binder with shown efficacy and additional effects on iron stores and use of intravenous (iv) iron and erythropoiesis-stimulating agents (ESAs). We provide detailed analyses of changes in iron/hematologic parameters and iv iron/ESA use at time points throughout the active control period of a phase 3 international randomized clinical trial. In all, 441 subjects were randomized (292 to FC and 149 to sevelamer carbonate and/or calcium acetate [active control (AC)]) and followed for 52 weeks. Subjects on FC had increased ferritin and transferrin saturation (TSAT) levels compared with subjects ...
Source: Journal of the American Society of Nephrology : JASN - September 30, 2015 Category: Urology & Nephrology Authors: Umanath, K., Jalal, D. I., Greco, B. A., Umeukeje, E. M., Reisin, E., Manley, J., Zeig, S., Negoi, D. G., Hiremath, A. N., Blumenthal, S. S., Sika, M., Niecestro, R., Koury, M. J., Ma, K.-N., Greene, T., Lewis, J. B., Dwyer, J. P., for the Collaborative S Tags: Clinical Research Source Type: research
Cost Effectiveness of Sucroferric Oxyhydroxide Compared with Sevelamer Carbonate in the Treatment of Hyperphosphataemia in Patients Receiving Dialysis, from the Perspective of the National Health Service in Scotland
Conclusions The use of PA21 versus SC in hyperphosphataemic patients being intolerant of calcium-based phosphate binders may be cost saving and yields only very limited disadvantages in terms of quality-adjusted survival. PA21 appears to be cost-effective from the perspective of the Scottish NHS. (Source: PharmacoEconomics)
Source: PharmacoEconomics - September 3, 2015 Category: Health Management Source Type: research
Renal formulas pretreated with medications alters the nutrient profile
Conclusions Pretreating formula with medications alters nutrients other than the intended target(s). Future studies should be aimed at predicting the loss of these nutrients or identifying alternative methods for managing serum potassium and phosphorus levels in formula-fed infants. The safety of pretreating formula with SPS suspension should also be examined. (Source: Pediatric Nephrology)
Source: Pediatric Nephrology - August 26, 2015 Category: Urology & Nephrology Source Type: research
Ferric Citrate, an Iron-Based Phosphate Binder, Reduces Health Care Costs in Patients on Dialysis Based on Randomized Clinical Trial Data
Conclusions Phosphate binding with FC reduces IV iron and ESA usage. Given the high cost burden of ESRD, our model demonstrates significant potential cost savings. Trial Registration ClinicalTrials.gov (NCT01191255) http://clinicaltrials.gov/ct2/show/NCT01191255. (Source: Drugs in R&D)
Source: Drugs in R&D - August 3, 2015 Category: Drugs & Pharmacology Source Type: research
Novel iron-based phosphate binders in patients with chronic kidney disease
Purpose of review: Management of hyperphosphatemia remains an integral component in the care of patients with chronic kidney disease on dialysis. In addition to dietary restriction and dialysis, oral phosphate binders remain a key strategy in the control of serum phosphorus levels in this population. We review two new oral phosphate binders that are currently marketed in the United States. Recent findings: Sucroferric oxyhydroxide was approved by the U.S. Food and Drug Administration (FDA) in November 2013. A recent international, multicenter study found the drug to be efficacious and noninferior to sevelamer carbonate in ...
Source: Current Opinion in Nephrology and Hypertension - June 12, 2015 Category: Urology & Nephrology Tags: MINERAL METABOLISM: Edited by Myles Wolf and David A. Bushinsky Source Type: research
Fp409 * sevelamer carbonate reduces phosphaturia but has no effect on serum c-terminal fibroblast growth factor 23 levels in stage 3b/4 ckd patients : the results of a french, multicenter, double-blind, placebo-control, randomized clinical trial
(Source: Nephrology Dialysis Transplantation)
Source: Nephrology Dialysis Transplantation - May 21, 2015 Category: Urology & Nephrology Authors: Liabeuf, S., Ryckelink, J. p., El Esper, N., Urena, P., Combe, C., Dussol, B., Fouque, D., Vanhille, P., Frimat, L., Thervet, E., Prie, D., Choukroun, G. Tags: CHRONIC KIDNEY DISEASE. BONE DISEASE Source Type: research
Sp643 * sevelamer carbonate vs. lanthanum carbonate vs. calcium acetate/magnesium carbonate in ckd patients on hemodialysis: a randomized study
(Source: Nephrology Dialysis Transplantation)
Source: Nephrology Dialysis Transplantation - May 21, 2015 Category: Urology & Nephrology Authors: Ekart, R., Bevc, S., Dvorsak, B., Hojs, N., Hren, M., Jakopin, E., Knehtl, M., Stropnik Galuf, T., Hojs, R. Tags: DIALYSIS. BONE DISEASE Source Type: research
Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients
Conclusions The serum phosphorus-lowering effect of sucroferric oxyhydroxide was maintained over 1 year and associated with a lower pill burden, compared with sevelamer. Sucroferric oxyhydroxide was generally well tolerated long-term and there was no evidence of iron accumulation. (Source: Nephrology Dialysis Transplantation)
Source: Nephrology Dialysis Transplantation - May 20, 2015 Category: Urology & Nephrology Authors: Floege, J., Covic, A. C., Ketteler, M., Mann, J. F. E., Rastogi, A., Spinowitz, B., Chong, E. M. F., Gaillard, S., Lisk, L. J., Sprague, S. M., on behalf of the Sucroferric Oxyhydroxide Study Group Tags: Intra- and extracorporeal treatments of kidney failure Source Type: research
The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial
Conclusions Ferric citrate was associated with similar phosphorus control compared to active control, with similar effects on markers of bone and mineral metabolism in dialysis patients. There was no evidence of protein-energy wasting/inflammation or aluminum toxicity, and fewer participants randomly assigned to ferric citrate had serious adverse events. Ferric citrate is an effective phosphate binder with a safety profile comparable to sevelamer and calcium acetate. (Source: American Journal of Kidney Diseases)
Source: American Journal of Kidney Diseases - May 9, 2015 Category: Urology & Nephrology Source Type: research
Sevalamer Hydrochloride, Sevelamer Carbonate and Lanthanum Carbonate: In Vitro and In Vivo Effects on Gastric Environment
Abstract Hyperphosphatemia is common in patients with chronic renal failure. Phosphate binders are associated with gastric intolerance, representing the main reason of drug discontinuation. The aim of this study was to compare the effects in vitro and in vivo of sevelamer hydrochloride (SH), sevelamer carbonate (SC) and lanthanum carbonate (LC) on gastric microenvironment. We have also evaluated the efficacy and tolerability of these drugs in hemodialysis (HD) patients. In vitro analysis: Dissolution time, ability to uptake phosphorus, changes in pH starting from gastric milieu and the amount of carbon dioxide (CO2) produc...
Source: Therapeutic Apheresis and Dialysis - April 1, 2015 Category: Hematology Authors: Giuseppe Coppolino, Silvia Lucisano, Laura Rivoli, Giorgio Fuiano, Antonino Villari, Iole Villari, Grazia Leonello, Antonio Lacquaniti, Domenico Santoro, Michele Buemi Tags: Original Article Source Type: research
Sucroferric Oxyhydroxide: A Review in Hyperphosphataemia in Chronic Kidney Disease Patients Undergoing Dialysis
In conclusion, sucroferric oxyhydroxide is a valuable treatment option for hyperphosphataemia in CKD patients on dialysis, providing an effective and generally well tolerated noncalcium-based phosphate binder therapy with a lower pill burden than sevelamer carbonate and the potential for improved treatment adherence. (Source: Drugs)
Source: Drugs - March 12, 2015 Category: Drugs & Pharmacology Source Type: research
Effects of Sevelamer Carbonate on Advanced Glycation End Products and Antioxidant/Pro-Oxidant Status in Patients with Diabetic Kidney Disease.
Abstract BACKGROUND AND OBJECTIVES: The primary goals were to re-examine whether sevelamer carbonate (SC) reduces advanced glycation end products (AGEs) (methylglyoxal and carboxymethyllysine [CML]), increases antioxidant defenses, reduces pro-oxidants, and improves hemoglobin A1c (HbA1c) in patients with type 2 diabetes mellitus (T2DM) and diabetic kidney disease (DKD). Secondary goals examined albuminuria, age, race, sex, and metformin prescription. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This two-center, randomized, intention-to-treat, open-label study evaluated 117 patients with T2DM (HbA1c>...
Source: Clinical Journal of the American Society of Nephrology : CJASN - February 20, 2015 Category: Urology & Nephrology Authors: Yubero-Serrano EM, Woodward M, Poretsky L, Vlassara H, Striker GE, on behalf of AGE-less Study Group Tags: Clin J Am Soc Nephrol Source Type: research
Cost- minimization analysis of the direct costs of sevelamer carbonate and lanthanum carbonate in the treatment of ckd-nd patients
The objective of this study is to perform cost - minimization analysis of the newly available medicines sevelamer carbonate (SC) and lanthanum carbonate (LC), for the treatment of hyperphosphatemia in CKD patients not on dialysis (CKD-ND) in Bulgaria. (Source: Value in Health)
Source: Value in Health - November 1, 2014 Category: Global & Universal Authors: M.K. Petrov, M. Dimitrova, G.I. Petrova Source Type: research
Sevelamer Carbonate mMarkedly Reduces Levothyroxine Absorption.
We report a the case of a young woman affected by hypothyroidism due to Hashimoto's thyroiditis, previously well compensated with a full replacement therapy (150 mcg/day of levothyroxine), presenting a clinical picture of myxedema, with a TSH=650 mU/L. Two years before she had started a dialysis treatment because of a chronic renal failure and she had been treated for the last 18 months with sevelamer carbonate, a phosphate binder. No improvement of clinical conditions nor reduction in TSH serum levels were obtained by increasing the dose of levothyroxine up to 300 mcg/day, whereas the euthyroidism was finally restored by ...
Source: Endocrine, Metabolic and Immune Disorders Drug Targets - September 2, 2014 Category: Endocrinology Authors: Iovino M, Iovine N, Petrosino A, Giagulli VA, Licchelli B, Guastamacchia E, Triggiani V Tags: Endocr Metab Immune Disord Drug Targets Source Type: research
Use of sevelamer to examine the role of intraluminal phosphate in the pathogenesis of secondary hyperparathyroidism.
CONCLUSIONS: Phosphate influx affected [PTH] in CKD by determining [P]f in the CDN. In some patients, low calcium influx may have blunted the effect of sevelamer on [PTH]. PMID: 25079864 [PubMed - in process] (Source: Clinical Nephrology)
Source: Clinical Nephrology - August 4, 2014 Category: Urology & Nephrology Authors: Phelps KR, Stote KS, Mason D Tags: Clin Nephrol Source Type: research
Hyperphosphatemic familial tumoral calcinosis: Response to acetazolamide and postulated mechanisms
We report on a 7‐year‐old African American boy who presented with severe HFTC requiring numerous surgical excisions. Tumors continued to appear and others reoccurred despite phosphate restriction and sevelamer carbonate. At the age of 9.5 years, acetazolamide (40 mg/kg/day) was added and resulted in mild metabolic acidosis (bicarbonate 25.3 mEq/L vs. 21.4 mEq/L, P
Source: American Journal of Medical Genetics Part A - March 25, 2014 Category: Genetics & Stem Cells Authors: Gal Finer, Heather E. Price, Richard M. Shore, Kenneth E. White, Craig B. Langman Tags: Clinical Report Source Type: research
Sevelamer carbonate lowers serum phosphorus effectively in haemodialysis patients: a randomized, double-blind, placebo-controlled, dose-titration study
Background Hyperphosphataemia in patients with advanced chronic kidney disease (CKD) is associated with adverse outcomes, including vascular calcification and higher mortality rates. While phosphate lowering is an integral aspect of CKD management, the efficacy and safety of phosphate binders in a contemporary cohort of Chinese haemodialysis patients (who have different genetics and dietary patterns than other populations) has not been previously described. Moreover, sparse data are available on strategies for optimal dose titration when transitioning from a calcium-based to a polymer-based phosphate binder. Methods This ...
Source: Nephrology Dialysis Transplantation - January 10, 2014 Category: Urology & Nephrology Authors: Chen, N., Wu, X., Ding, X., Mei, C., Fu, P., Jiang, G., Li, X., Chen, J., Liu, B., La, Y., Hou, F., Ni, Z., Fu, J., Xing, C., Yu, X., Huang, C., Zuo, L., Wang, L., Hunter, J., Dillon, M., Plone, M., Neylan, J. Tags: Chronic Kidney Disease Source Type: research
Differences in gastrointestinal calcium absorption after the ingestion of calcium-free phosphate binders
In conclusion, these two noncalcium-containing phosphate-binding agents showed a differential effect on gastrointestinal calcium absorption. These findings may help to improve the management of calcium balance in patients with renal failure, including concomitant use of vitamin D. (Source: AJP: Renal Physiology)
Source: AJP: Renal Physiology - January 1, 2014 Category: Urology & Nephrology Authors: Behets, G. J., Dams, G., Damment, S. J., Martin, P., De Broe, M. E., D'Haese, P. C. Tags: ARTICLES Source Type: research
Sevelamer revisited: pleiotropic effects on endothelial and cardiovascular risk factors in chronic kidney disease and end-stage renal disease
Endothelial dysfunction underlies multiple cardiovascular consequences of chronic kidney disease (CKD) and antecedent diabetes or hypertension. Endothelial insults in CKD or end-stage renal disease (ESRD) patients include uremic toxins, serum uric acid, hyperphosphatemia, reactive oxygen species, and advanced glycation endproducts (AGEs). Sevelamer carbonate, a calcium-free intestinally nonabsorbed polymer, is approved for hyperphosphatemic dialysis patients in the US and hyperphosphatemic stage 3–5 CKD patients in many other countries. Sevelamer has been observed investigationally to reduce absorption of AGEs, bacte...
Source: Therapeutic Advances in Cardiovascular Disease - December 10, 2013 Category: Cardiology Authors: Rastogi, A. Tags: Review Source Type: research
Differences in gastrointestinal calcium absorption after ingestion of calcium-free phosphate binders.
In conclusion, these two non calcium-containing phosphate binding agents showed a differential effect on gastrointestinal calcium absorption. These findings may help to improve management of calcium balance in patients with renal failure, including concomitant use of vitamin D. PMID: 24197066 [PubMed - as supplied by publisher] (Source: Am J Physiol Renal P...)
Source: Am J Physiol Renal P... - November 6, 2013 Category: Urology & Nephrology Authors: Behets GJ, Dams G, Damment SJ, Martin P, De Broe ME, D'Haese PC Tags: Am J Physiol Renal Physiol Source Type: research
Epicardial adipose tissue predicts mortality in incident hemodialysis patients: a substudy of the Renagel in New Dialysis trial
Background Epicardial adipose tissue (EAT) has been described in the general population as an independent risk marker for incident coronary artery disease. In hemodialysis patients, it correlates with other markers of cardiovascular disease, but it is unknown if it is associated with adverse events. Methods post hoc analysis of the Renagel in New Dialysis (RIND) patients study, a randomized trial of sevelamer versus calcium-based phosphate binders in 109 incident hemodialysis patients, followed for all-cause mortality for a median of 49.3 months. Patients underwent baseline cardiac computed tomography imaging within 120 d...
Source: Nephrology Dialysis Transplantation - September 27, 2013 Category: Transplant Surgery Authors: D'Marco, L. G., Bellasi, A., Kim, S., Chen, Z., Block, G. A., Raggi, P. Tags: Intra- and Extracorporeal Treatments of Kidney Failure Source Type: research
A regenerable potassium and phosphate sorbent system to enhance dialysis efficacy and device portability: an in vitro study
Conclusion RES-A and FeOOH are suitable, regenerizable sorbents for potassium and phosphate removal in dialysate regeneration. Use of zirconium carbonate and ZIR-hydr may further increase phosphate adsorption, but may compromise sorbent regenerability. Use of polymeric amines for phosphate adsorption may enhance sorbent regenerability. Calcium and magnesium preloading considerably reduced net adsorption of these ions. (Source: Nephrology Dialysis Transplantation)
Source: Nephrology Dialysis Transplantation - September 11, 2013 Category: Urology & Nephrology Authors: Wester, M., Simonis, F., Gerritsen, K. G., Boer, W. H., Wodzig, W. K., Kooman, J. P., Joles, J. A. Tags: Intra- and Extracorporeal Treatments of Kidney Failure Source Type: research
Comparison of sevelamer and calcium carbonate on endothelial function and inflammation in patients on peritoneal dialysis
ConclusionsTreatment with sevelamer carbonate has beneficial effects compared with calcium carbonate in decreasing inflammation and improving EF in patients with T2DM on PD. (Source: Journal of Renal Care)
Source: Journal of Renal Care - March 1, 2013 Category: Urology & Nephrology Authors: Sudha P. Chennasamudram, Tanjila Noor, Tetyana L. Vasylyeva Tags: Original Research Source Type: research